Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nadia Rose
Institution:
SARomics Biostructures (Sweden)
Observed institutions:
Medicon Village,
SARomics Biostructures (Sweden)
ORCID:
0000-0002-8729-064X
Observed ORCID:
0000-0002-8729-064X
OpenAlex ID:
A5027352248
Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition
2022
·
Philippe Billiald
, Alexandre Slater
, et al.
·
Blood Advances
·
41
PDF
The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2022
·
Michelle H. Nelson
, Sara Fritzell
, et al.
·
Molecular Cancer Therapeutics
·
12
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
2023
·
Karin Enell Smith
, Sara Fritzell
, et al.
·
Cancer Immunology Immunotherapy
·
10
PDF
Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
2024
·
Pauline Malinge
, Xavier Chauchet
, et al.
·
mAbs
·
3
Supplementary Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2025
·
Michelle H. Nelson
, Sara Fritzell
, et al.
PDF
Supplementary Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2023
·
Michelle H. Nelson
, Sara Fritzell
, et al.
PDF
Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2023
·
Michelle H. Nelson
, Sara Fritzell
, et al.
Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2023
·
Michelle H. Nelson
, Sara Fritzell
, et al.
Supplementary Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2023
·
Michelle H. Nelson
, Sara Fritzell
, et al.
Show more works
View as search
Works count:
9
Citation count:
66
H-index:
3
I10-index:
3
Year
Topic
Type